Ximelagatran Versus Warfarin in the Prevention of Atrial Fibrillation–Related Stroke: Both Sides of the Story | Zendy

Luca Testa | Zendy; W. van Gaal | Zendy; Pierfrancesco Agostoni | Zendy; Antonio Abbate | Zendy; Graziana Trotta | Zendy; Giuseppe BiondiZoccai | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ximelagatran Versus Warfarin in the Prevention of Atrial Fibrillation–Related Stroke: Both Sides of the Story

Author(s) -

Luca Testa,

W. van Gaal,

Pierfrancesco Agostoni,

Antonio Abbate,

Graziana Trotta,

Giuseppe BiondiZoccai

Publication year - 2007

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.107.486969

Subject(s) - medicine , atrial fibrillation , stroke (engine) , warfarin , commonwealth , embolic stroke , cardiology , ischemic stroke , law , mechanical engineering , engineering , ischemia , political science

To the Editor:We have carefully read the interesting article by Akins et al1 focusing on a pivotal issue in the prevention of atrial fibrillation-related stroke. The authors pooled the data from high-risk (previous stroke/TIA) versus nonhigh-risk (no previous stroke/TIA) patients included in SPORTIF III2 and SPORTIF V3 trials in which the direct thrombin inhibitor ximelagatran was compared with warfarin in the primary and secondary prevention of thromboembolic stroke. The authors concluded stating that ximelagatran was at least as effective as warfarin.In our opinion, some points deserve attention and a deeper examination. Our group recently published nonfunded/nonbiased meta-analytic …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research